Table 1.
LEN+EVE data sources for three separate ITCs applying hazard ratios.
Fig 1.
Network of trials included in the Bucher ITCs for a/mRCC.
Table 2.
Baseline characteristics comparison of patients in the clinical trials.
Table 3.
Indirect treatment comparisons of progression-free survival: Hazard ratio (95% CI) for LEN + EVE versus comparators.
Table 4.
Indirect treatment comparisons of overall survival: Hazard ratio (95% CI) for LEN + EVE versus other treatments.
Fig 2.
Network of trials for the NMA applying fractional polynomials.
Fig 3.
Hazard ratios over time for progression-free survival (fixed-effects second-order polynomial).
CAB, cabozantinib; EVE, everolimus; LEV, lenvatinib; NIV, nivolumab; PFS, progression-free survival Notes: Solid line is median and dotted lines 95% credible intervals. Hazard ratios based on average estimates for everolimus over the three studies (μ0, μ1, μ2) per Jansen 2011 [17].
Fig 4.
Hazard ratio over time for overall survival (fixed-effects first-order polynomial).
CAB, cabozantinib; EVE, everolimus; LEV, lenvatinib; NIV, nivolumab; OS, overall survival; Notes: Solid line is median and dotted lines 95% credible intervals. Hazard ratios based on average estimates for everolimus over the three studies (μ0, μ1) per Jansen 2011 [17].